3 Firms Guide Goldman Sachs On Buying Synthon Stake <https://www.law360.co.uk/financial-services-uk/articles/2274283?nl_pk=a94fc7ab-a9ab-4472-a647-9bf619c7b000&utm_source=newsletter&utm_medium=email&utm_campaign=financial-services-uk&utm_content=2024-12-17&read_main=1&nlsidx=0&nlaidx=7>
By Najiyya Budaly The alternative investment arm of Goldman Sachs said Monday that it plans to buy a majority stake in the drugmaker Synthon from British investment firm BC Partners LLP, in a deal that values the Dutch company at a reported €2 billion ($2.1 billion).
